title: Devic's neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus.
abstract: Neuropsychiatric forms of systemic lupus erythematosus (SLE) vary, most commonly consisting of seizures, psychiatric disturbances, or focal central nervous deficits. This is a new case of neuromyelitis optica or Devic's syndrome during the course of SLE. Few reports of this association exist in the literature. Our objective is to report this unique case of Devic's neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus. A 28-year-old woman had been diagnosed as having SLE with cutaneous and articular involvement in 1987 when she was 17 years old. She was treated with a synthetic antimalarial agent associated with corticosteroids. In 1994, during the fourth month of pregnancy, she had signs of transverse myelitis with a sensory level at T6 associated with an optic neuropathy suggesting a Devic's syndrome. The patient was managed by plasmapheresis sessions and intravenous corticosteroids. Transverse myelitis recurred postpartum and three years later at the same thoracic level. Management by bolus administration of a steroid and cyclophosphamide resulted in remission again. There have only been around a dozen reports in the literature of patients who had both Devic's neuromyelitis optica and SLE. Magnetic resonance imaging is contributive to diagnosis and therapeutic follow-up, showing spinal cord lesions with increased intensity on T2-weighted sequences. Although the clinical course of the present patient has been favourable so far, the prognosis of this neurologic disease is generally considered to be poor with elevated mortality.
authors.affiliation: Service de médecine interne, Hôpital Haut Lévêque, Centre Hospitalier Universitaire de Bordeaux, France.
authors.forename: F
authors.initials: F
authors.lastname: Bonnet
authors.forename: P
authors.initials: P
authors.lastname: Mercié
authors.forename: P
authors.initials: P
authors.lastname: Morlat
authors.forename: C
authors.initials: C
authors.lastname: Hocke
authors.forename: C
authors.initials: C
authors.lastname: Vergnes
authors.forename: E
authors.initials: E
authors.lastname: Ellie
authors.forename: J F
authors.initials: JF
authors.lastname: Viallard
authors.forename: I
authors.initials: I
authors.lastname: Faure
authors.forename: J L
authors.initials: JL
authors.lastname: Pellegrin
authors.forename: J
authors.initials: J
authors.lastname: Beylot
authors.forename: B
authors.initials: B
authors.lastname: Leng
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000473:pathology / Q000628:therapy; D008279:Magnetic Resonance Imaging; D009471:Neuromyelitis Optica / Q000150:complications* / Q000473:pathology / Q000628:therapy; D010956:Plasmapheresis; D011247:Pregnancy; D011248:Pregnancy Complications / Q000473:pathology* / Q000628:therapy
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide